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Abstract 
Review on CTDSPL, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
 
Identity 
Other names: C3orf8, HYA22, PSR1, RBSP3, 
SCP3 
HGNC (Hugo): CTDSPL 
Location: 3p22.2 
 
Diagram shows the different transcripts of CTDSPL (Brown, Blue, Grey and Maroon boxes). Beginning of boxes 
represents transcription start sites. Filled areas represent translated regions. The larger form, CTDSPL B is shown as CTDSPL 
001, whereas the smaller form, CTDSPL A is shown as CTDSPL 002. Image adapted from Ensembl.org. 
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Schematic diagram of full length RBSP3 protein, showing different domains. Adapted from PDB O15194. Data origin/ 
Colour codes: Data in Green originates from UniProtKB; Data in Yellow originates from Pfam, by interacting with the HMMER3 
website; Data in Grey has been calculated using BioJava. Protein disorder predictions are based on JRONN, a Java 
implementation of RONN. (a. Red- Potentially disordered region. b. Blue- Probably ordered region. Hydropathy has been 
calculated using a sliding window of 15 residues and summing up scored from standard hydrophobicity tables. a. Red- 
Hydrophobic. b. Blue- Hydrophilic); Data in blue originates from PDB. Secstruc- Secondary structure projected from 
representative PDB entries onto the UniProt sequence. (a. Red box - Helix. b. Yellow box - Sheet. c. Grey tube- Coil); Data in red 
indicates combined ranges of Homology Models from SBKB and the Protein Model Portal. 
 
 
DNA/RNA 
Description 
Located in the short (p) arm of chromosome 3, the 
length of the CTDSPL gene is about 122.5 kb, 
contains 8 exons and is arranged in a telomere to 
centromere orientation. 
Transcription 
The full length transcript of CTDSLP is 4459 bp 
(Ensembl, Transcript ID ENST00000443503). A 
total of 8 transcripts can be generated, out of which 
5 are protein coding, 1 undergoes nonsense 
mediated decay, while the rest 2 do not code for a 
protein product. However, two splice variants of 
CTDSPL, the smaller CTDSPL A (lacking exon 3, 
therefore short of 33 bp, 11 amino acids) and the 
full length CTDSPL B were identified by Kashuba 
et al., 2004. 
Interesting observation: The transcription start 
site for CTDSPL A and CTDSPL B are different 
(from ensemble.org). While the larger B form has a 
shorter 5'UTR, the smaller A form has a larger 
5'UTR, although their translation start sites remain  
common. Difference in the size of the 5'UTR may 
account for differential splicing between the 
isoforms. 
Pseudogene 
None reported. 
Protein 
Description 
The full length CTDSPL protein (CTDSPL B) is 
276 amino acids in length, with a molecular weight 
of 31 kD.  
The smaller protein, CTDSPL A is 265 amino acids 
in length (amino acids 79- 89 missing) and 29.9 kD 
in weight. Amino acids 102-260 contain the FCP1 
homology domain, which contains an essential 
protein serine phosphatase that dephosphorylates 
the C-terminal domain (CTD) of RNA polymerase 
II. 
Localisation 
Both nuclear and cytoplasmic (Maiti et al., 2012; 
Sarkar et al., 2013). 
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CTDSPL Protein expression data from MOPED1, PaxDb2 and MAXQB3. 1. MOPED - Eugene Kolker, Bioinformatics & High-
throughput Analysis Lab, Seattle Children's Research Institute. 2. PaxDb - Christian von Mering, Bioinformatics Group, Institute 
of Molecular Life Sciences, University of Zurich. 3. MAXQB - Matthias Mann, Department of Proteomics and Signal Transduction, 
Max-Planck Institute of Biochemistry, Germany. The data was normalized as follows: 1. For each sample, ppm protein values 
were calculated, if not provided so by data sources. For each sample from MAXQB, iBAQ expression values were divided by 
sum of values of each sample, and multiplied by 1000000. For all samples, data was gene centrically aggregated by summing 
expression values of all isoforms for each gene. 2. For better visualization of graphs, expression values are drawn on a root 
scale, which is an intermediate between log and linear scales as used for our mRNA expression graphs (Safran et al., 2003). 
 
 
Function 
- CTDSPL is a serine phosphatase which regulates 
cell growth and differentiation. It dephosphorylates 
RB at serine 807/ 811 (hence called RB1 serine 
phosphatase from human chromosome 3), thereby 
increasing RB-E2F interaction and halting the cell 
cycle at G1/S boundary (Kashuba et al., 2004). 
- It also inactivates RNA polymerase-II by 
preferential dephosphorylation of 'Ser-5' within the 
tandem 7 residues repeats in the C-terminal domain 
(CTD) of the largest RNA polymerase II subunit, 
thus controlling the transcription machinery (hence 
called carboxy-terminal domain, RNA polymerase 
II, polypeptide A small phosphatase-like) (Yeo et 
al., 2003). 
- Studies also suggest that CTDSPL/RBSP3 might 
function as a transcriptional co-repressor, inhibiting 
transcription of neuronal genes in non-neuronal 
cells (Yeo et al., 2005), and may also act as a 
phosphatase of Smad1, Smad2/Smad3 and Snail 
(Wu et al., 2009; Sapkota et al., 2006). 
Homology 
Chimpanzee, Rhesus monkey, dog, cow, mouse, 
chicken, zebrafish, S.cerevisiae, K.lactis, 
E.gossypii, S.pombe, M.oryzae, and N.crassa show 
conserved RBSP3 gene (Source NCBI 
homologene). 
RBSP3 and miRNAs 
1. miRNA 100 
- RBSP3 is a bonafide target for miRNA 100. 
- miRNA 100 binds to the 3`UTR of RBSP3 in 
regions conserved in humans, rats and mice. 
- RBSP3 expression is inversely co-related with the 
expression of miRNA 100 in 76.5% AML cases. 
2. miRNA 26a (has-miR-26a-1) 
- miRNA 26a resides in the intron of RBSP3. 
- It is concomitantly expressed with RBSP3 during 
the cell cycle. 
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Different organisms showing homology in RBSP3 protein. 
 
 
Interacting proteins of RBSP3, using String network. 
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Mutations and copy number variations in different organs. Red bar: Loss. Grey bar: Gain. Adapted from COSMIC gene 
analysis. 
 
 
Mutations 
Germinal 
None reported. 
Implicated in 
Cervical cancer 
Note 
- High deletion (48%, 45% cases) and methylation 
(26%, 25% cases) was seen in CIN and CACX 
respectively (Mitra et al., 2010). 
- Reduced mRNA expression was seen in CACX 
(Mitra et al., 2010). 
- RBSP3B (larger, active isoform) was under-
expressed in CACX (Mitra et al., 2010).  
- In HPV infected cervical cancer, high deletion 
(42% cases) was observed, with significant  
variation (p<0.05) between metastatic (64%) and 
non-metastatic (32%) cases (Anedchenko et al., 
2007) 
- Altogether, copy number change was seen in 51% 
cases (Anedchenko et al., 2007). 
- Decreased expression was seen in 64% cases, with 
significant difference between metastatic (83%) and 
non-metastatic (52%) cases (Anedchenko et al., 
2007). 
- Increase in expression was also observed in some 
cases (Anedchenko et al., 2007). 
- Altogether, change in expression was in 79% of 
cases (Anedchenko et al., 2007). 
Prognosis 
RBSP3 alterations (deletion, methylation) were 
significantly associated with poor patient outcome 
and posed 4.5-13 times risk of survival 
(Anedchenko et al., 2007). 
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Oncogenesis 
Inactivation of RBSP3 was an early event in 
cervical carcinogenesis (Mitra et al., 2010). 
Breast cancer 
Note 
- Study population was divided into two groups, 
Group A (≤40 yrs, early onset) and Group B (>40 
yrs, late onset) (Sinha et al., 2008).  
- High deletion (30%, 24% cases) and methylation 
(38%, 32% cases) were observed in Groups A and 
B respectively (Sinha et al., 2008). 
- 28.9 ± 39.1 fold reduction in expression of RBSP3 
was observed in about 33 - 40% of the tumors 
(Sinha et al., 2008). 
- Homozygous deletion (10-18%) was observed for 
RBSP3 (Senchenko et al., 2004). 
Prognosis 
Patients belonging lower to age of onset (≤40 yrs) 
with alterations of RBSP3 had poor disease 
outcome (Sinha et al., 2008). 
Oncogenesis 
Higher alterations of RBSP3 were observed in 
patients belonging to the lower age of onset (Group 
A) (Sinha et al., 2008). 
Acute lymphoid leukemia (ALL) 
Note 
Promoter methylation was seen in RBSP3 in 24% 
of ALL patients. 
Prostate cancer 
Note 
GWAS study using Affymetrix 100K SNP 
GeneChip with GEE model showed that the SNP, 
rs9311171 (G/ T), located within RBSP3, had a 
notable GEE p value (1.8x 10 -6). 
Oncogenesis 
GEE p value 1.8x 10 -6 indicates that this SNP 
within RBSP3 plays a role in tumor progression. 
Non - small cell lung cancer (NSCLC) 
Note 
- Reduction of expression of RBSP3 was obtained 
for both adenocarcinoma (AC) and squamous cell 
carcinoma (SCC) (Senchenko et al., 2008). 
- Downregulation was both genetic and epigenetic 
(Senchenko et al., 2008). 
- For ACs, decrease in level of expression was in 
88% cases and 70% cases of metastatic and non-
metastatic tumors respectively, whereas for SCCs, 
it was in 88% cases for both metastatic and non-
metastatic tumors (Senchenko et al., 2008). 
- Decrease in mRNA in ACs was due to deletion 
(25% cases) and promoter methylation (38% cases), 
whereas for SCCs, it was in 30% and 80% cases for 
deletion and methylation respectively (Senchenko  
 
 
et al., 2008). 
- Fold decrease in expression of RBSP3 in AC and 
SCC was 78% and 88% respectively, with overall 
85% decrease in expression of RBSP3 in NSCLC 
(Senchenko et al., 2010). 
Oncogenesis 
Deletion and methylation of promoter of RBSP3 
are responsible for reduction in expression of the 
protein and play important roles in progression of 
NSCLC (Senchenko et al., 2008). 
Reduction of expression of RBSP3 is required for 
development of lung adenocarcinomas (Senchenko 
et al., 2010). 
Ovarian cancer 
Note 
Deletion/Methylation of RBSP3 were observed in 
33% cases. 
Oncogenesis 
RBSP3 deletion/methylation can be used as a 
biomarker for ovarian cancer in combination with 
other studied markers. 
Head and neck squamous cell 
carcinoma (HNSCC) 
Note 
- Deletion of RBSP3 in dysplasia and HNSCC was 
in 24% and 32% cases respectively (Ghosh et al., 
2010). 
- Promoter methylation was observed in 39% and 
38% cases of dysplasia and HNSCC samples 
respectively (Ghosh et al., 2010). 
- Fold reduction of mRNA in the tumors was 33.6 ± 
9.4 (Ghosh et al., 2010). 
- While normal tissues expressed the larger RBSP3 
B form, tumors either showed no expression of 
RBSP3, or preferentially expressed the smaller, less 
active form, RBSP3 A (Ghosh et al., 2010). 
Expression of RBSP3 decreases from pre-malignant 
to malignant lesions (Maiti et al., 2012). 
Expression of RBSP3 was seen to be increased 
from pre-neoadjuvant chemotherapy tumors to 
post-therapy tumors (Sarkar et al., 2013). 
Prognosis 
Patients with RBSP3 alterations show poor survival 
(Ghosh et al., 2010). 
Oncogenesis 
Early alteration of RBSP3 takes place in head and 
neck cancers (Ghosh et al., 2010). 
Loss of expression of RBSP3 was seen to be 
required for progression from malignant to invasive 
cancer (Maiti et al., 2012). 
Regain of expression of RBSP3 in post-therapy 
tumors may be one of the reasons of shrinkage of 
tumors due to neoadjuvant chemotherapy (Sarkar et 
al., 2013). 
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Lung, renal, breast, cervical and 
ovarian cancers 
Note 
High frequencies of somatic mutations in RBSP3 in 
different cancers suggesting it may underlay the 
mutator phenotype of cancer. 
Acute myeloid leukemia (AML) 
Note 
RBSP3 might have a crucial role in myeloid cell 
differentiation towards granulocyte/monocyte 
lineages through pRB-E2F pathway. 
Cell lines 
Note 
Leukemia cell lines RAJI, BJAB (B cell leukemia) 
and HL-60 (myeloid leukemia) showed 
hypermethylation of RBSP3 promoter. 
Hepatocellular carcinoma (HCC) in 
mouse model system 
Note 
RBSP3 shows increase in expression (RNA, 
protein) upon treatment with the chemopreventive 
agent Amarogentin. 
Oncogenesis 
Increase in expression of RBSP3 might play a role 
in chemoprevention upon treatment with 
amarogentin. 
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